Forty-eight states and territories have settled with generic drugmaker Glenmark Pharmaceuticals for $29.6 million over allegations it conspired with competitors to inflate generic drug prices, bringing total settlements in a multistate price-fixing case to more than $96 million. Consumers who bought certain generics made by Glenmark or four other manufacturers — Lannett, Bausch, Apotex and Heritage — between May 2009 and December 2019 may be eligible for a share. The process right now is registration, not a payout: state attorneys general are directing eligible buyers to confirm eligibility while the case against dozens of remaining defendants continues.
A $96 Million Total, Five Settlements Deep
Connecticut Attorney General William Tong led a coalition of 48 states and territories in announcing the Glenmark settlement on July 15, the latest in a series Connecticut has directed since first suing generic drugmakers in 2016. The Glenmark deal follows earlier settlements with Heritage and Apotex, and with Lannett and Bausch, that together total $66.95 million — bringing the combined recovery across all five companies to $96.55 million.
The states allege the five manufacturers took part in a broader conspiracy stretching back years, in which competing executives coordinated on pricing and market allocation for numerous generic prescription drugs through industry dinners, golf outings, phone calls and text messages. Court filings describe defendants using phrases like “fair share” and “playing nice in the sandbox” to describe agreements that allegedly kept generic prices — the versions of drugs meant to be cheaper alternatives to brand names — artificially high.
Each participating state receives its own slice of the settlement based on population and purchasing data; Colorado’s estimated share of the Glenmark payout alone is $406,518, while Connecticut’s is $388,868. As part of the deal, Glenmark also agreed to cooperate with the states’ ongoing litigation against the 33 corporate defendants and 25 individual executives who have not settled, with the first trial anticipated in Hartford, Connecticut, in late 2026.
Colorado Attorney General Phil Weiser, whose state’s share of the Glenmark deal is $406,518, framed the underlying conduct as a betrayal of the competitive market generic drugs are supposed to preserve. “Generic drugs are supposed to make health care more affordable through competition, not become the subject of illegal price-fixing schemes,” Weiser said in announcing the settlement, adding that “Colorado families, businesses, and public health programs all pay the price” when manufacturers coordinate instead of compete. As part of the deal, Glenmark also agreed to a series of internal reforms intended to strengthen antitrust compliance and curb the kind of executive-to-executive coordination the states say inflated prices for more than a decade.
Free retirement updates: Keep more of your Social Security and savings with plain-English updates on the changes, deadlines, and costly mistakes retirees miss. Subscribe free.
Register Now — the Claims Process Comes Later
A federal court in Connecticut has already given preliminary approval to the Glenmark settlement, clearing the way for the $29.6 million in restitution to move toward eligible consumers and the state coalition — but preliminary approval is not the same as money going out the door. Settlements of this size typically require a claims-administration process, a final approval hearing and a distribution plan before any individual payment is calculated or mailed.
For now, the states are directing eligible buyers to a registration step, not a claim form: anyone who purchased a generic prescription drug made by Glenmark, Lannett, Bausch, Apotex or Heritage between May 1, 2009, and December 31, 2019, can call, email or visit the coalition’s dedicated website to determine eligibility. That determination step typically precedes the actual claims-filing window, which state attorneys general say will open later as the settlement moves through the remaining court process.
The purchase window is unusually long — more than a decade — because it spans the years investigators say the alleged price-fixing conspiracy was active. A consumer does not need a receipt from a specific 2009 purchase to inquire; the eligibility-determination process is built to match buyers against pharmacy and insurance records tied to the named drugs and manufacturers during that period.
A Bigger Case Still Playing Out
Glenmark’s settlement is one piece of a much larger set of cases Connecticut has led since 2016, when the first complaint named Heritage and 17 other corporate defendants over 15 generic drugs. A second complaint filed in 2019 named Teva Pharmaceuticals and 21 other manufacturers, and a third complaint — the one set to go to trial first — focuses on 80 topical generic drugs that together account for billions of dollars in U.S. sales.
The five settlements arrived on a staggered timeline rather than all at once: Heritage and Apotex resolved their share of the case in 2024, Lannett and Bausch followed with a settlement earlier in 2026, and Glenmark’s $29.6 million deal in July brought the running total across all five companies to $96.55 million. Each resolving company has been required to keep cooperating with the states’ case against the defendants who have not settled, a structure the states say has helped build the evidentiary record — including a two-volume notebook of contemporaneous notes one cooperating witness kept documenting his calls with competing executives — now underpinning the case heading toward trial.
Investigators built the cases on evidence from cooperating witnesses, a database of more than 20 million documents and phone records covering more than 600 sales and pricing employees across the generic drug industry. Several individual executives, including two former Heritage Pharmaceuticals officials, have separately reached settlement agreements and are cooperating with the states’ case against the companies and executives who have not yet resolved the allegations.
The open question for anyone who bought a generic prescription drug in that decade-long window is timing: registering now secures a place in the process, but the actual size and schedule of any payment depends on a trial that has not yet happened and a claims process the states have not yet opened. Consumers waiting for a formal notice that a distribution has opened may be waiting for a step that, in a case this size, is still a court date away.
This article was researched and drafted with the assistance of artificial intelligence.
More Financial Reading
